Natera

YTD

ALL

Trade Natera 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTRA

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT).

CEO

Stephen Leonard Chapman

CEOStephen Leonard Chapman

Employees

6,140

Employees6,140

Headquarters

Austin, Texas

HeadquartersAustin, Texas

Founded

2003

Founded2003

Employees

6,140

Employees6,140

NTRA Key Statistics

Market cap

29.08B

Market cap29.08B

Price-Earnings ratio

-123.80

Price-Earnings ratio-123.80

Dividend yield

—

Dividend yield—

Average volume

1.64M

Average volume1.64M

High today

$210.67

High today$210.67

Low today

$202.26

Low today$202.26

Open price

$204.37

Open price$204.37

Volume

1.04M

Volume1.04M

52 Week high

$256.36

52 Week high$256.36

52 Week low

$131.81

52 Week low$131.81

Stock Snapshot

As of today, Natera(NTRA) shares are valued at $203.45. The company's market cap stands at 29.08B, with a P/E ratio of -123.80.

On 2026-05-23, Natera(NTRA) stock moved within a range of $202.26 to $210.67. With shares now at $203.45, the stock is trading +0.6% above its intraday low and -3.4% below the session's peak.

Trading volume for Natera(NTRA) stock has reached 1.04M, versus its average volume of 1.64M.

Over the past 52 weeks, Natera(NTRA) stock has traded between a high of $256.36 and a low of $131.81.

NTRA News

Investing.com 1d

Natera to present 35 oncology abstracts at ASCO meeting - Investing.com

...

Nasdaq 2d

Natera's EXPAND Trial Enrollment Crosses 2,000 Patient Milestone

Natera NTRA recently announced that its EXPAND clinical trial evaluating the Fetal Focus single-gene noninvasive prenatal test (NIPT) has exceeded 2,000 patient...

TipRanks 2d

Natera announces expansion into Austin, creating largest sequencing factory

Natera (NTRA) announced a significant expansion of its operations. At its North Austin headquarters campus, Natera will unveil two major expansion projects: a s...

Analyst ratings

90%

of 20 ratings

Buy

90%

Hold

10%

Sell

More NTRA News

TipRanks 3d

Natera announces Expand trial enrolled over 2,000 patients

Natera (NTRA) announced that the Expand clinical trial has enrolled over 2,000 patients, more than doubling enrollment in the last 12 months. Expand is a prospe...

Simply Wall St 3d

FDA Nod For Signatera MRD Blood Test Might Change The Case For Investing In Natera

In May 2026, Natera, Inc. received FDA approval for Signatera CDx as the first blood-based minimal residual disease companion diagnostic to guide adjuvant atezo...

Simply Wall St 5d

A Look At Natera Valuation After Recent Share Price Weakness

Advertisement Stock performance snapshot and recent context Natera (NTRA) has drawn fresh investor attention after its share price closed at US$186.36, with t...

People also own

Based on the portfolios of people who own NTRA. This list is generated using Robinhood data, and it’s not a recommendation.

Modine

Flowserve

iShares MSCI Emerging Mar…

ResMed

CSX

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.